Summary
A potent high-titre glucagon antibody pool was used to induce a state of acute glucagon deficiency in order to investigate the importance of glucagon in maintaining euglycaemia in the fed and fasted anaesthetised rat. Binding characteristics of the antiserum and evidence of its neutralisation of the biological effects of exogenous glucagon are described. The amount of antibody administered was capable of neutralising up to 12 times the total content of glucagon (approximately 1nmol) in the rat pancreas. The hyperglycaemic response to 1.43 nmol exogenous glucagon was significantly inhibited in the rat by glucagon antibodies given intravenously or intraperitoneally (p < 0.001). However, no changes in plasma glucose occurred in rats fasted 16 h (4.35±0.1 mmol/l or 24 h (4.0±0.05 mmol/l) after antibody administration. The same dose of glucagon antibodies produced no change in plasma glucose (6.1±0.2 mmol/l), immunoreactive insulin (1.85±0.05 μg/l) or immunoreactive somatostatin (110±30 ng/l) in rats after antibody administration. Antibody excess, equivalent to a binding capacity for glucagon of 40 nmol/l in the plasma of recipient animals, was demonstrable at all times after passive immunisation. The absence of any affect on glucose concentrations following immunoneutralisation of glucagon suggests that glucagon secretion may not be a major factor in the maintenance of euglycaemia in the rat.
Article PDF
Similar content being viewed by others
References
Moloney PJ, Coral M (1955) Antigenicity of insulin: diabetes induced by specific antibodies. Biochem J 59: 179–185
Armin J, Grant RT, Wright PH (1960) Experimental diabetes in rats produced by patenteral administration of anti-insulin serum. J Physiol 153: 146–165
Chey WY, Kim MS, Lee KY, Chang T (1979) Effect of rabbit antisecritin serum on postprandial pancreatic secretion in dogs. Gastroenterology 77: 1268–1275
Ebert R, Illmer K, Creutzfeldt W (1979) Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats. Gastroenterology 76: 515–523
Lipschutz W, Hughes W, Cohen S (1972) The genesis of lower esophageal sphincter pressure: its identification through the use of gastrin antiserum. J Clin Invest 51: 522–529
Chiba T, Kadowaki S. Taminato T, Chihara K, Seino Y, Matsukura S, Fujita T (1981) Effect of antisomatostatin gamma-globulin on gastrin release in rats. Gastroenterology 81: 321–326
Grey N, McGuigan JE, Kipnis DM (1970) Neutralization of endogenous glucagon by high titre glucagon antiserum. Endocrinology 86: 1383–1388
Barling P, Beloff-Chain H (1973) Studies on the administration of glucagon and insulin antibodies to rats. Horm Metab Res 5: 154–159
Epand RH, Douglas RJ (1973) The effect of glucagon antibodies on plasma glucose and insulin levels. Biochim Biophys Acta 320: 741–744
Hoist JJ, Galbo H, Richter EA (1978) Neutralization of glucagon by antiserum as a tool in glucagon physiology. Lack of depression of basal glucose after antiserum treatment in rats. J Clin Invest 62: 182–190
Heding LG (1971) Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia 7: 10–19
Heding LG (1972) Determination of total serum insulin (IRI) in insulintreated diabetic patients. Diabetologia 8: 260–266
Jorgensen KH, Larsen VD (1972) Purification of 125I-glucagon by anion exchange chromatography. Horm Metab Res 4: 223–224
De Vane GW, Siler TM, Yen SSC (1974) Acute suppression of insulin and glucose levels by synthetic somatostatin in normal human subjects. J Clin Endocrinol Metab 38: 913–915
Gerich JE, Lorenzi M, Schneider V, Forsham PH (1974) Effect of somatostatin on plasma glucose and insulin responses to glucagon and tolbutamide in man. J Clin Endocrinol Metab 39: 1057–1060
Cherrington AD, Chiasson JL, Liljenquist JE, Jennings AS, Keller V, Lacy WW (1976) The role of insulin and glucagon in the regulation of basal glucose production in the post-absorptive dog. J Clin Invest 58: 1407–1418
Sacca L, Sherwin R, Felig P (1977) Somatostatin alters the hepatic response to glucagon and epinephrine in vivo independent of insulin and glucagon availability. Diabetologia 13: 428–429
Lins PE, Efendic S (1976) Hyperglycaemia induced by somatostatin in normal subjects. Horm Metab Res 8: 497–498
Luyckx A (1974) Etude de la sécrétion de l'insulin et du glucagon. Faculté de Médecine, Université de Liège, Liège 122
Rodbell M, Kraus H, Pohl SL, Birnbaumer L (1971) The glucagonsensitive adenyl cyclase system in plasma membranes of rat liver. J Biol Chem 246: 1861–1871
Frohman LA, Reichlin M, Sokal JE (1970) Immunological and biological properties of antibodies to a glucagon-serum albumin polymer. Endocrinology 87: 1055–1061
Dobbs R, Sakurai H, Sasaki H, Faloona G, Valverde I, Baetens D, Orci L, Unger R (1975) Glucagon: role in the hyperglycaemia of diabetes mellitus. Science 187: 544–547
Dunbar JC, Walsh MF, Foa PP (1978) The serum glucose response to glucagon suppression with somatostatin, insulin or antiglucagon serum in depancreatized rats. Diabetologia 14: 53–58
Nishino T, Shima K, Shimomura Y, Tanaka R, Kodaiva T, Imagawa K, Kumahara Y (1980) A study of the physiological role of glucagon. Passive immunization with antiserum specific for pancreatic glucagon in rats. Endocrinol Japn (SR No. 1): 109–113
Cherrington SD, Liljenquist JE, Shulman GI, Williams PE, Lacy WW (1979) Importance of hypoglycaemia-induced glucose production during isolated glucagon deficiency. Am J Physiol 236: E263-E271
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tan, K., Tsiolakis, D. & Marks, V. Effect of glucagon antibodies on plasma glucose, insulin and somatostatin in the fasting and fed rat. Diabetologia 28, 435–440 (1985). https://doi.org/10.1007/BF00280887
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00280887